A Clinical Trial for People with Social Anxiety
Social Anxiety Disorder (SAD)
Social Anxiety Disorder (SAD) impacts over 30 million Americans, causing intense and persistent anxiety in various social situations. Whether meeting new people, speaking in meetings, dating, job interviews, or everyday interactions like talking to a cashier, individuals with SAD experience profound fear of being embarrassed, judged, or rejected.
This anxiety can severely disrupt daily life, affecting work, school, and social activities, leading to avoidance and missed opportunities. Currently, there are no FDA-approved, as-needed treatments for SAD. Existing treatments, such as antidepressants, take several weeks to work, do not work for everyone, and often have unwanted side effects.
If you have been feeling this way for at least 6 months, you may have SAD.
Fasedienol—A Potential New Approach for the Treatment of Social Anxiety Disorder (SAD)
Fasedienol is a nasal spray currently in development as a quick-acting treatment for SAD that can be taken as-needed to help reduce anxiety in stressful situations.
Unlike traditional anxiety medications that are taken every day, take weeks to work, and may have unwanted side effects, it is thought that fasedienol may work to reduce fear and anxiety quickly by sending signals to your brain.
If you qualify, you may be eligible to join the study to explore if fasedienol may help reduce your anxiety.
Who is the Fasedienol Study For?
- People who suffer from social anxiety or are diagnosed with SAD
- People who are between the age of 18 to 65
- People who have normal functioning sense of smell
Participating in the Study
This study will evaluate if fasedienol nasal spray works to reduce anxiety and its safety compared to a placebo (an inactive substance that looks exactly like the study drug but does not contain any active ingredient).
You will be expected to visit the site for 4 visits, 1 week apart 4 weeks in a row. After the first 4 weeks of the study, eligible subjects may have the option to continue the study for up to 12 months and use fasedienol as-needed in their daily lives and visit the site once a month.
Participants will be compensated for their participation, and reimbursement for travel costs to and from clinical sites may be available.